Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults over 18 years old of any gender
- People who are willing and able to give their informed consent to take part in the study
- People who have been diagnosed with cirrhosis (scarring of the liver) that is classed as Child-Pugh A or B (a measure of how well the liver is still working), caused by at least one of the following: chronic Hepatitis B, chronic Hepatitis C, alcohol-related liver disease, non-alcoholic fatty liver disease, or haemochromatosis (iron build-up in the liver)
- The cirrhosis diagnosis must be confirmed by one of the following: a liver biopsy showing advanced scarring, a specialised liver scan or blood test result above a certain threshold (confirm with trial site for exact values), visible signs of liver complications on an endoscopy or scan, or clear imaging evidence of cirrhosis such as a lumpy liver surface and enlarged spleen on ultrasound or CT scan
Who may not be able to join:
- People who have been diagnosed with liver cancer (hepatocellular carcinoma), either now or at any point in the past
- People who have had a liver transplant, or who are currently on a waiting list for one
- People whose cirrhosis is classed as Child-Pugh C (the most severe category of liver function decline)
- People who, in their treating doctor's view, have another serious health condition likely to be life-limiting within the next 12 months
- People who, in their treating doctor's view, are not considered suitable for routine liver cancer monitoring (HCC surveillance)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.; Specificity of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.; Positive/Negative predictive values of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.